Niagen Bioscience Inc. is a nicotinamide adenine dinucleotide science and healthy-aging research company. Niagen Bioscience Inc., formerly known as ChromaDex Corp., is based in LOS ANGELES.
| Revenue (Most Recent Fiscal Year) | $129.42M |
| Net Income (Most Recent Fiscal Year) | $8.55M |
| PE Ratio (Current Year Earnings Estimate) | 16.84 |
| PE Ratio (Trailing 12 Months) | 30.88 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.05 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.57 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 83.52 |
| Pre-Tax Margin (Trailing 12 Months) | 17.04% |
| Net Margin (Trailing 12 Months) | 13.43% |
| Return on Equity (Trailing 12 Months) | 22.20% |
| Return on Assets (Trailing 12 Months) | 15.58% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.12 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 3.36 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.03 |
| Earnings per Share (Most Recent Fiscal Year) | $0.18 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.20 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 79.81M |
| Free Float | 72.31M |
| Market Capitalization | $394.24M |
| Average Volume (Last 20 Days) | 1.24M |
| Beta (Past 60 Months) | 2.11 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.39% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.41% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |